In the Chemotherapy as Adjuvant for Locally Recurrent breast cancer (CALOR) trial—the only randomized trial for iLRR, the authors showed the necessity of adjuvant chemotherapy in patients with completely resected iLRR, especially in estrogen receptor (ER)-negative breast cancer (7). The gene discussed is ESR1; the disease is breast cancer.